INTRODUCTION: Survival after pulmonary metastasectomy for soft tissue sarcoma (STS) has been lower than in osteosarcoma (14-40% versus 40-50%). With improved patient selection criteria and advanced chemotherapy agents, we hypothesized that survival after metastasectomy for STS has improved in recent years. METHODS: Retrospective study of 48 patients undergoing pulmonary metastasectomy for STS between 1995 and 2007. Potential predictors of overall survival and disease-free survival (DFS) were examined using the log-rank test or Cox regression. Multivariate analysis was conducted using Cox regression. RESULTS: Overall survival after initial metastasectomy was 67% and 52% at 3 and 5 years, respectively; DFS was 17% and 10% at 3 and 5 years. Univariate analysis indicated that ≤2 pulmonary metastases (p = 0.03), diameter of largest metastasis ≤2 cm (p = 0.09), and the absence of extrapulmonary metastases (p = 0.10) were associated with longer overall survival. Absence of extrapulmonary metastases (p = 0.07) and smaller size of the largest pulmonary metastasis (p = 0.06) were associated with longer DFS. Before 2001, 46.7% of patients received adjuvant chemotherapy versus 72.7% after (p = 0.10). Neither use of chemotherapy nor chemotherapy type was related to overall survival or DFS. CONCLUSION: Five-year overall survival is substantially higher after pulmonary metastasectomy for STS in our study relative to previously published results (52% versus 14-40%). This improvement does not seem to be the result of greater use of, or newer, chemotherapeutic regimens. Among potential explanations, improved patient selection is the most likely factor.
INTRODUCTION: Survival after pulmonary metastasectomy for soft tissue sarcoma (STS) has been lower than in osteosarcoma (14-40% versus 40-50%). With improved patient selection criteria and advanced chemotherapy agents, we hypothesized that survival after metastasectomy for STS has improved in recent years. METHODS: Retrospective study of 48 patients undergoing pulmonary metastasectomy for STS between 1995 and 2007. Potential predictors of overall survival and disease-free survival (DFS) were examined using the log-rank test or Cox regression. Multivariate analysis was conducted using Cox regression. RESULTS: Overall survival after initial metastasectomy was 67% and 52% at 3 and 5 years, respectively; DFS was 17% and 10% at 3 and 5 years. Univariate analysis indicated that ≤2 pulmonary metastases (p = 0.03), diameter of largest metastasis ≤2 cm (p = 0.09), and the absence of extrapulmonary metastases (p = 0.10) were associated with longer overall survival. Absence of extrapulmonary metastases (p = 0.07) and smaller size of the largest pulmonary metastasis (p = 0.06) were associated with longer DFS. Before 2001, 46.7% of patients received adjuvant chemotherapy versus 72.7% after (p = 0.10). Neither use of chemotherapy nor chemotherapy type was related to overall survival or DFS. CONCLUSION: Five-year overall survival is substantially higher after pulmonary metastasectomy for STS in our study relative to previously published results (52% versus 14-40%). This improvement does not seem to be the result of greater use of, or newer, chemotherapeutic regimens. Among potential explanations, improved patient selection is the most likely factor.
Authors: Jarrod D Predina; Andrew D Newton; Christopher Corbett; Michael Shin; Lydia Frenzel Sulfyok; Olugbenga T Okusanya; Edward J Delikatny; Shuming Nie; Colleen Gaughan; Doraid Jarrar; Taine Pechet; John C Kucharczuk; Sunil Singhal Journal: J Thorac Cardiovasc Surg Date: 2018-12-14 Impact factor: 5.209
Authors: Nisreen S Ezuddin; Juan Pretell-Mazzini; Raphael L Yechieli; Darcy A Kerr; Breelyn A Wilky; Ty K Subhawong Journal: Skeletal Radiol Date: 2018-05-21 Impact factor: 2.199
Authors: Joachim Pfannschmidt; Gerlinde Egerer; Marc Bischof; Michael Thomas; Hendrik Dienemann Journal: Dtsch Arztebl Int Date: 2012-10-05 Impact factor: 5.594
Authors: Lars H Lindner; Saskia Litière; Stefan Sleijfer; Charlotte Benson; Antoine Italiano; Bernd Kasper; Christina Messiou; Hans Gelderblom; Eva Wardelmann; Axel Le Cesne; Jean-Yves Blay; Sandrine Marreaud; Nadia Hindi; Ingrid M E Desar; Alessandro Gronchi; Winette T A van der Graaf Journal: Int J Cancer Date: 2018-02-14 Impact factor: 7.396
Authors: Neel P Chudgar; Murray F Brennan; Kay See Tan; Rodrigo R Munhoz; Sandra P D'Angelo; Manjit S Bains; James Huang; Bernard J Park; Prasad S Adusumilli; William D Tap; David R Jones Journal: Ann Thorac Surg Date: 2017-11-02 Impact factor: 4.330